Preoperative chemotherapy and radiotherapy for esophageal carcinoma
From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patien...
Gespeichert in:
Veröffentlicht in: | The Journal of thoracic and cardiovascular surgery 1992-05, Vol.103 (5), p.887-895 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 895 |
---|---|
container_issue | 5 |
container_start_page | 887 |
container_title | The Journal of thoracic and cardiovascular surgery |
container_volume | 103 |
creator | Naunheim, Keith S. Petruska, Paul J. Roy, Tapan S. Andrus, Charles H. Johnson, Frank E. Schlueter, Jean M. Baue, Arthur E. |
description | From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p < 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95) |
doi_str_mv | 10.1016/S0022-5223(19)34912-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72900589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022522319349128</els_id><sourcerecordid>72900589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhq2qiC60PwEpp7YcAp54_XVCaFU-JCSQ2kq9WY49S4ySdWpnt-LfYwiCY0_WeJ53ZvQQcgT0BCiI05-UNk3Nm4Z9B33MlhqaWn0gC6Ba1kLxPx_J4g35RA5yfqCUSgp6n-wDF1pKWJDVXcI4YrJT2GHlOhzi1JVyfKzsxlfJ-vD2sY6pwhzHzt6j7StnkwubONjPZG9t-4xfXt9D8vvix6_VVX1ze3m9Or-p3ZKrqWbWUaY9ZwBrAV5IKvWSeeBWg-Kstd630jPBRYuNLAcqACHQttgKvqSeHZKv89wxxb9bzJMZQnbY93aDcZuNbDSlXOkC8hl0KeaccG3GFAabHg1Q8yzPvMgzz2YMaPMiz6iSO3pdsG0H9O-p2Vbpf5v7Xbjv_oWEJg-27wsN5mFyGSgz3CglC3k2k1h87AImk13AjUNfUm4yPob_3PIEzAqMDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72900589</pqid></control><display><type>article</type><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</creator><creatorcontrib>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</creatorcontrib><description>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p < 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/S0022-5223(19)34912-8</identifier><identifier>PMID: 1569771</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Actuarial Analysis ; Adenocarcinoma - mortality ; Adenocarcinoma - therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - therapy ; Chemotherapy, Adjuvant ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - therapy ; Esophagectomy ; Female ; Fluorouracil - administration & dosage ; Humans ; Male ; Middle Aged ; Preoperative Care ; Radiotherapy, High-Energy</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 1992-05, Vol.103 (5), p.887-895</ispartof><rights>1992 American Association for Thoracic Surgery</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</citedby><cites>FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-5223(19)34912-8$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1569771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naunheim, Keith S.</creatorcontrib><creatorcontrib>Petruska, Paul J.</creatorcontrib><creatorcontrib>Roy, Tapan S.</creatorcontrib><creatorcontrib>Andrus, Charles H.</creatorcontrib><creatorcontrib>Johnson, Frank E.</creatorcontrib><creatorcontrib>Schlueter, Jean M.</creatorcontrib><creatorcontrib>Baue, Arthur E.</creatorcontrib><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p < 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</description><subject>Actuarial Analysis</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagectomy</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Preoperative Care</subject><subject>Radiotherapy, High-Energy</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAQhq2qiC60PwEpp7YcAp54_XVCaFU-JCSQ2kq9WY49S4ySdWpnt-LfYwiCY0_WeJ53ZvQQcgT0BCiI05-UNk3Nm4Z9B33MlhqaWn0gC6Ba1kLxPx_J4g35RA5yfqCUSgp6n-wDF1pKWJDVXcI4YrJT2GHlOhzi1JVyfKzsxlfJ-vD2sY6pwhzHzt6j7StnkwubONjPZG9t-4xfXt9D8vvix6_VVX1ze3m9Or-p3ZKrqWbWUaY9ZwBrAV5IKvWSeeBWg-Kstd630jPBRYuNLAcqACHQttgKvqSeHZKv89wxxb9bzJMZQnbY93aDcZuNbDSlXOkC8hl0KeaccG3GFAabHg1Q8yzPvMgzz2YMaPMiz6iSO3pdsG0H9O-p2Vbpf5v7Xbjv_oWEJg-27wsN5mFyGSgz3CglC3k2k1h87AImk13AjUNfUm4yPob_3PIEzAqMDw</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>Naunheim, Keith S.</creator><creator>Petruska, Paul J.</creator><creator>Roy, Tapan S.</creator><creator>Andrus, Charles H.</creator><creator>Johnson, Frank E.</creator><creator>Schlueter, Jean M.</creator><creator>Baue, Arthur E.</creator><general>Elsevier Inc</general><general>AATS/WTSA</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920501</creationdate><title>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</title><author>Naunheim, Keith S. ; Petruska, Paul J. ; Roy, Tapan S. ; Andrus, Charles H. ; Johnson, Frank E. ; Schlueter, Jean M. ; Baue, Arthur E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-3ac039d5311f61d6707943d15a91853baddb7d3656be2756981166eabeb6540d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Actuarial Analysis</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagectomy</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Preoperative Care</topic><topic>Radiotherapy, High-Energy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naunheim, Keith S.</creatorcontrib><creatorcontrib>Petruska, Paul J.</creatorcontrib><creatorcontrib>Roy, Tapan S.</creatorcontrib><creatorcontrib>Andrus, Charles H.</creatorcontrib><creatorcontrib>Johnson, Frank E.</creatorcontrib><creatorcontrib>Schlueter, Jean M.</creatorcontrib><creatorcontrib>Baue, Arthur E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naunheim, Keith S.</au><au>Petruska, Paul J.</au><au>Roy, Tapan S.</au><au>Andrus, Charles H.</au><au>Johnson, Frank E.</au><au>Schlueter, Jean M.</au><au>Baue, Arthur E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative chemotherapy and radiotherapy for esophageal carcinoma</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>103</volume><issue>5</issue><spage>887</spage><epage>895</epage><pages>887-895</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><abstract>From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period. This treatment was well tolerated; 44 patients (94%) completed a full course of therapy, 40 (85%) had relief from dysphagia, and 21 (45%) noted either weight gain or no net weight loss. One patient (2%) died of complications (tracheoesophageal fistula, perforated ulcer) during chemotherapy and radiotherapy. The remaining 46 patients were referred for operation. Six refused because of excellent relief of their dysphagia, and one was denied operation. Thirty-nine patients went to operation, and 34 (83%) had lesions that were resectable. Eight of the 39 surgically treated patients (21%) had no evidence of residual tumor identified in the resected specimens. One of these complete responders died 7 weeks postoperatively after multiple complications (3% operative mortality rate). Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease. Actuarial survival in this present series was significantly better than that of our 1980 to 1985 historical control patients (p < 0.005). There was no difference between patients with squamous carcinoma and those with adenocarcinoma with regard to the prevalence of complete response or long-term survival. Survival of the seven patients who did not undergo operation was comparable with that of the 34 patients in whom esophagectomy was performed. This study suggests that combined preoperative chemotherapy plus radiotherapy for esophageal cancer is well tolerated, provides excellent palliation of symptoms, allows for a high rate of resectability, is equally effective for squamous carcinoma and adenocarcinoma, and provides encouraging early results with regard to long-term survival. The data also call into question the role of esophagectomy, particularly in patients who have a complete response to preoperative therapy. (J Thorac Cardiovasc Surg 1992;103:887-95)</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1569771</pmid><doi>10.1016/S0022-5223(19)34912-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-5223 |
ispartof | The Journal of thoracic and cardiovascular surgery, 1992-05, Vol.103 (5), p.887-895 |
issn | 0022-5223 1097-685X |
language | eng |
recordid | cdi_proquest_miscellaneous_72900589 |
source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Actuarial Analysis Adenocarcinoma - mortality Adenocarcinoma - therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - therapy Chemotherapy, Adjuvant Cisplatin - administration & dosage Combined Modality Therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - therapy Esophagectomy Female Fluorouracil - administration & dosage Humans Male Middle Aged Preoperative Care Radiotherapy, High-Energy |
title | Preoperative chemotherapy and radiotherapy for esophageal carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A39%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20chemotherapy%20and%20radiotherapy%20for%20esophageal%20carcinoma&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Naunheim,%20Keith%20S.&rft.date=1992-05-01&rft.volume=103&rft.issue=5&rft.spage=887&rft.epage=895&rft.pages=887-895&rft.issn=0022-5223&rft.eissn=1097-685X&rft_id=info:doi/10.1016/S0022-5223(19)34912-8&rft_dat=%3Cproquest_cross%3E72900589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72900589&rft_id=info:pmid/1569771&rft_els_id=S0022522319349128&rfr_iscdi=true |